8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – May 12, 2022

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: 610-594-2900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 12, 2022, West Pharmaceutical Services, Inc. (the “Company” or "West") announced the appointment of Bernard J. Birkett, Chief Financial Officer, to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead the Company's Global Operations and Global Supply Chain. After six years of dedicated service, the Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo, has announced his resignation to pursue other interests, with a departure date of July 2022.

The Company has also announced other leadership changes and additions, including the appointment of Cindy Reiss-Clark as the Chief Commercial Officer, which are described in further detail in the Company's press release.

Item 7.01 Regulation FD Disclosure.

On May 12, 2022, the Company issued a press release announcing the executive leadership appointments. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

4

Document

Exhibit 99.1

West Announces Executive Leadership Appointments

Exton, PA, May 12, 2022 — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West’s Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company’s Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

The Company also announced that West’s Senior Vice President, Global Markets and Commercial Solutions, Cindy Reiss-Clark has been appointed to the role of Chief Commercial Officer. Additionally, West’s Senior Vice President, Commercial Products and Emerging Markets, Chris Ryan has been appointed to Senior Vice President, Containment and Glass Systems. The Company also announced the hiring of Kathy dePadua as Vice President and Chief Quality Officer. Ms. dePadua joins West from GE Healthcare where she most recently held the position of Global Quality Executive for the Life Care Solutions Strategic business unit. She brings a wealth of experience to the company having served in various Quality and Regulatory leadership positions over the last 30 years in the medical device and pharma industry.

“I am pleased to announce the appointments of Bernard, Cindy and Chris to these new executive leadership roles, and I am extremely pleased to welcome Kathy to the West team as we continue to advance the importance of our purpose as a global leader in integrated containment and delivery of injectable medicines,” said Eric M. Green, President and Chief Executive Officer, West. “We sincerely appreciate David’s leadership and contributions to the growth and success of West over the past six years, and wish him well in his future endeavors. With the strength of our Global Operations team, I am confident as we seamlessly transition to Bernard's leadership, our Company is well positioned for future growth."

About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.

Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.